Patents Issued in January 14, 2020
-
Patent number: 10532068Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.Type: GrantFiled: May 8, 2018Date of Patent: January 14, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
-
Patent number: 10532069Abstract: Compositions and methods are disclosed for the treatment of osteoarthritis. The compositions comprising combinations of hyaluronic acid, glucosamine, and chondroitin sulfate, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.Type: GrantFiled: June 2, 2017Date of Patent: January 14, 2020Assignee: DEPUY SYNTHES PRODUCTS, INC.Inventors: Brooks J. Story, Scott A. Wadsworth, William R. Parrish, Uri Herzberg, Donna Torres, Benjamin A. Byers, Julia Hwang, Dongling Su
-
Patent number: 10532070Abstract: Iron-doped apatite nanoparticles (IDANPs) are useful for the prevention, treatment, or alleviation of signs or symptoms associated with viral activation or infection. IDANPs have demonstrated a significant influence over herpes simplex virus 1 (HSV-1) infection of two mammalian cell lines. Specifically, IDANPs decreased HSV-1 infection of African Green Monkey kidney epithelial (Vero) cells by 84% and HSV-1 infection of human lung bronchus (BEAS-2B) cells by 71%. IDANPs consist of hydroxyapatite (HA) doped with iron. HA is a mineral known to be biocompatible and analogous to the inorganic constituent of mammalian bone and teeth and has been approved by the Food and Drug Administration (FDA) for many applications in medicine and dentistry. Lactate Dehydrogenase (LDH) and XTT (2,3-Bis 2-methoxy-4-nitro-5-sulfophenyl-2H-tetrazolium-5-carboxanilide inner salt) cytotoxicity assays revealed that IDANPs are largely non-toxic to Vero, BEAS-2B, and human cervical cancer (HeLa) cells lines.Type: GrantFiled: February 22, 2018Date of Patent: January 14, 2020Inventors: Jessica M. Gregory, Jack L. Skinner, Marisa L. Pedulla, M. Katie Hailer
-
Patent number: 10532071Abstract: The invention concerns high-performance adsorbents based on activated carbon of high meso- and macroporosity which are present in the form of discrete grains of activated carbon, wherein: at least 55% of the total pore volume of the high-performance adsorbents are formed by pores (i.e. meso- and macropores) having pore diameters of more than 20 ?, the high-performance adsorbents have a measure of central tendency pore diameter of more than 25 ?, and the high-performance adsorbents have a BET surface area of at least 1250 m2/g. These high-performance adsorbents are obtainable by a novel process comprising specific two-stage activation, and have, in addition to the aforementioned properties, an excellent abrasion and bursting resistance, so that they are useful for a multiplicity of different applications.Type: GrantFiled: January 4, 2018Date of Patent: January 14, 2020Assignee: Blücher GmbHInventors: Bertram Böhringer, Sven Fichtner, Jann-Michael Giebelhausen
-
Patent number: 10532072Abstract: Described are methods of producing an autologous composition useful for treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal. The method comprises preparing an anti-inflammatory/anti-catabolic component of the autologous composition comprising IL-1ra and TIMPs. An anti-inflammatory/anti-catabolic component is prepared comprising: collecting blood from the mammal; delivering the blood to a tube; incubating the blood at a temperature of from about 37° C. to about 39° C. for about 24 hours, preferably in the presence of sodium citrate; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component.Type: GrantFiled: September 30, 2015Date of Patent: January 14, 2020Assignee: Antnor LimitedInventors: Anthony Galea, Irina Brokhman
-
Patent number: 10532073Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.Type: GrantFiled: June 26, 2019Date of Patent: January 14, 2020Assignee: Io Therapeutics, Inc.Inventors: Roshantha A. Chandraratna, Martin E. Sanders
-
Patent number: 10532074Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.Type: GrantFiled: July 23, 2019Date of Patent: January 14, 2020Assignee: Io Therapeutics, Inc.Inventors: Roshantha A. Chandraratna, Martin E. Sanders
-
Patent number: 10532075Abstract: The invention relates to the use of a composition comprising at least one extract of propolis, having at least one of the following properties: —an antioxidant value (ORAC) greater than or equal to 500 mmol TE/100 g of dry extract, —a flavones and flavonols content greater than or equal to 5.5% by weight with respect to the total weight of dry material of the extract, —a flavanones and dihydroflavanols content greater than or equal to 5% by weight with respect to the total weight of dry material of the product, in order to prevent and/or limit the side effects of chemotherapy.Type: GrantFiled: December 11, 2015Date of Patent: January 14, 2020Assignee: POLLENERGIEInventor: Nicolas Cardinault
-
Patent number: 10532076Abstract: The present technology relates to foodstuffs that contain a substantially anhydrous fatty food that is solid at room temperature and comprises a substantially anhydrous probiotic bacterial preparation dispersed therein. Methods of making such substantially anhydrous fatty foods are also disclosed.Type: GrantFiled: March 30, 2018Date of Patent: January 14, 2020Assignee: Brandeis UniversityInventor: Daniel Perlman
-
Patent number: 10532077Abstract: A virus-like particle of Senecavirus A, the particle including a structural protein VP0, a structural protein VP1 and a structural protein VP3. The structural protein VP0 is encoded by a gene sequence represented by SEQ ID NO: 1. The structural protein VP1 is encoded by a gene sequence represented by SEQ ID NO: 2. The structural protein VP3 is encoded by a gene sequence represented by SEQ ID NO: 3.Type: GrantFiled: May 15, 2019Date of Patent: January 14, 2020Assignee: LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCESInventors: Huichen Guo, Shiqi Sun, Shichong Han, Hu Dong, Xiaoran Guo, Hong Yin, Jianxun Luo
-
Patent number: 10532078Abstract: The invention relates to a method for producing an extract of a matrix of vegetable origin, particularly a plant, characterised in that the matrix of vegetable origin undergoes a mechanical treatment consisting in extruding the matrix of vegetable origin in an extruder, in association or not with a heat treatment, in the presence of an aqueous solution containing at least one hydrotrope agent, particularly at a concentration at least equal to the minimum hydrotrope concentration thereof, followed by an operation of recovering the extract.Type: GrantFiled: March 18, 2016Date of Patent: January 14, 2020Assignee: PIERRE FABRE DERMO-COSMETIQUEInventors: Anne Mandeau, Mathieu Leti
-
Patent number: 10532079Abstract: Extracts or beverages whose ratio between the content of 2,5-piperazinedione,3,6-bis(phenylmethyl)-,(3S,6S)-(unit: ?g/100 g) and Brix (Bx) is 6 (?g/100 g)/Bx or more are good in flavor and feeling on the tongue and further have a good appearance.Type: GrantFiled: March 28, 2016Date of Patent: January 14, 2020Assignees: SUNTORY HOLDINGS LIMITED, SUNTORY BEVERAGE & FOOD ASIA PTE. LTD.Inventors: Hideki Matsubayashi, Kenji Yamamoto, Hiroshi Watanabe, Lee Kian Hong
-
Patent number: 10532080Abstract: Disclosed herein is an aqueous solution comprising from 80 mg A/mL to 400 mg A/mL of a sulfomethylated polymyxin and a cartridge containing the same. In addition it is disclosed an aqueous solution for use in therapy.Type: GrantFiled: October 1, 2015Date of Patent: January 14, 2020Assignee: XELLIA PHARMACEUTICALS APSInventor: Nenad Bencic
-
Patent number: 10532081Abstract: The embodiments include methods of ameliorating or preventing the worsening or progression and/or ameliorating or preventing the worsening or lack of improvement of symptoms of BPH in mammals, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.Type: GrantFiled: September 7, 2016Date of Patent: January 14, 2020Assignee: NYMOX CORPORATIONInventor: Paul Averback
-
Patent number: 10532082Abstract: The present invention relates to a SOCS1-derived peptide for use in chronic complications of diabetes, particularly ocular, renal, nerve and vascular complications, as well as compositions containing same and isolated polynucleotides encoding same. The present invention also relates to the SOCS1-derived peptide for topical use in the treatment and/or prevention of neurodegenerative diseases of the retina, particularly in the early stages of diabetic retinopathy and other diseases of the retina in which neurodegeneration plays an essential role.Type: GrantFiled: May 27, 2015Date of Patent: January 14, 2020Assignees: Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma De MadridInventors: Jesús Egido De Los Rios, Carmen Gómez Guerrero, Rafael Simó Canonge, Cristina Hernández Pascual
-
Patent number: 10532083Abstract: The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and polynucleotides for use in treating diseases or disorders of energy homeostasis. Said polypeptides, polynucleotides and pharmaceutical compositions may be administered locally, in particular locally into the visceral adipose tissue. Another aspect of the invention relates to a cosmetic product and the use of said cosmetic product for reducing body weight, in particular for reducing abdominal adipose tissue.Type: GrantFiled: February 13, 2015Date of Patent: January 14, 2020Assignee: Technische Universität MünchenInventors: Sören Westphal, Tobias Fromme, Martin Klingenspor
-
Patent number: 10532084Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.Type: GrantFiled: November 2, 2018Date of Patent: January 14, 2020Assignee: EYEBIO KOREAInventor: Jae Wook Yang
-
Patent number: 10532085Abstract: The present invention relates to a bioactive agent capable of increasing the intracellular concentration and/or activity of Hsp70 for use in the treatment of a lysosomal storage disease which arise from a defect in an enzyme whose activity is not directly associated with the presence of lysosomal BMP as a co-factor; such as glycogen storage diseases, gangliosidoses, neuronal ceroid lipofuscinoses, cerebrotendinous cholesterosis, Wolman's disease, cholesteryl ester storage disease, disorders of glycosaminoglycan metabolism, mucopolysaccharidoses, disorders of glycoprotein metabolism, mucolipidoses, aspartylglucosaminuria, fucosidosis, mannosidoses, and sialidosis type II.Type: GrantFiled: May 19, 2017Date of Patent: January 14, 2020Assignee: Orphazyme A/SInventors: Thomas K. Jensen, Anders Mørkeberg Hinsby
-
Patent number: 10532086Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.Type: GrantFiled: December 6, 2017Date of Patent: January 14, 2020Assignee: BIO-CANCER TREATMENT INTERNATIONAL LIMITEDInventors: Gernot Schabbauer, Stephan Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
-
Patent number: 10532087Abstract: Disclosed are methods and compositions for treatment of a subject having a biliary disorder. The methods include administering a therapeutically effective amount of a serine protease inhibitor to a subject in need thereof. The biliary disorder include biliary atresia, a biliopathy, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), and combinations thereof. In certain aspects, the serine protease inhibitor may be a protease inhibitor rC1 Inhibitor.Type: GrantFiled: May 24, 2016Date of Patent: January 14, 2020Assignee: Children's Hospital Medical CenterInventor: Pranav-Kumar Shivakumar
-
Patent number: 10532088Abstract: The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR?) and provides adoptive cellular therapies using an agonist of ROR?, populations of lymphocyte cells that have been exposed to an agonist of ROR?, populations of dendritic cells that have been exposed to an agonist of ROR?, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR? to a patient.Type: GrantFiled: February 27, 2015Date of Patent: January 14, 2020Assignee: Lycera CorporationInventors: Gary D. Glick, Peter L. Toogood, Xiao Hu, Thomas D. Aicher, Laura Lee Celeste, Xikui Liu, Clarke B. Taylor, Chad A. Van Huis
-
Patent number: 10532089Abstract: Contemplated cancer treatments comprise recursive analysis of patient-, cancer-, and location-specific neoepitopes from various biopsy sites of a patient after treatment or between successive rounds of immunotherapy and/or chemotherapy to inform further immunotherapy. Recursive analysis preferably includes various neoepitope attributes to so identify treatment relevant neoepitopes.Type: GrantFiled: October 12, 2016Date of Patent: January 14, 2020Assignees: NANTOMICS, LLC, NANT HOLDINGS IP, LLCInventors: Stephen Charles Benz, Kayvan Niazi, Patrick Soon-Shiong, Andrew Nguyen
-
Patent number: 10532090Abstract: The present invention provides a vaccine composition comprising: (i) an adjuvant; and (ii) at least one fusion peptide conjugated to a carrier protein, wherein the carrier protein is the diphtheria toxin variant CRM-197 (GenBank Accession No. 1007216A) and wherein the at least one fusion peptide comprises two or more non-contiguous B cell epitopes of Her2/neu selected from the group consisting of SEQ ID Nos:1-7 and 15-60 and amino acid sequences that have at least 85% identity to any of the foregoing. The present invention also extends to pharmaceutical compositions and methods of using the vaccine and/or pharmaceutical compositions, as herein described, for the treatment or prevention of a cancer characterised by the expression or over-expression of Her2/neu in a patient in need thereof.Type: GrantFiled: April 15, 2016Date of Patent: January 14, 2020Assignee: Biolife Science QLD LimitedInventor: Ursula Wiedermann
-
Patent number: 10532091Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: July 10, 2019Date of Patent: January 14, 2020Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
-
Patent number: 10532092Abstract: Foot-and-mouth disease virus like particles, the particles including a structural protein VP0, a structural protein VP1 including a mineralization peptide, a structural protein VP3, and a calcium phosphate coat. The structural protein VP1 including a mineralization peptide is encoded by a gene sequence represented by SEQ ID NO. 7, SEQ ID NO. 8 or SEQ ID NO. 9. The structural protein VP0 is encoded by a gene sequence represented by SEQ ID NO. 2. The structural protein VP3 is encoded by a gene sequence represented by SEQ ID NO. 3. The calcium phosphate coat covers the structural protein VP0, the structural protein VP1 including a mineralization peptide, and the structural protein VP3.Type: GrantFiled: July 4, 2018Date of Patent: January 14, 2020Assignees: LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES, ZHEJIANG UNIVERSITYInventors: Huichen Guo, Shiqi Sun, Ping Du, Zhidong Teng, Ruikang Tang, Ruibo Zhao, Jiaxi Ru, Yanquan Wei, Yun Zhang, Yuan Gao, Junwu Ma, Xiangtao Liu, Hong Yin
-
Patent number: 10532093Abstract: The present invention relates to a thermostable freeze dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses multivalent thermostable liquid, powder or cake based rotavirus vaccine formulation prepared using the freeze drying process, such that the said vaccine formulation possess improved heat-stability, easy to use and transport and highly affordable thereby meeting the requirements of developing and low income country's vaccination program. The said freeze dried rotavirus vaccine formulation along with reconstitution buffer is so engineered to be suitable for filling in appropriate packaging containers/ closures so designed such that they reduce the logistics requirement for storage.Type: GrantFiled: July 16, 2015Date of Patent: January 14, 2020Assignee: MDS WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.Inventors: Davinder Gill, Madhu Madan, Sachin Kale, Tarun Sharma, Nidhi Shukla, Deepa Sikriwal, Robert Evans
-
Patent number: 10532094Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.Type: GrantFiled: November 9, 2018Date of Patent: January 14, 2020Assignee: Bavarian Nordic A/SInventors: Cédric Cheminay, Robin Steigerwald, Paul Chaplin
-
Patent number: 10532095Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.Type: GrantFiled: December 19, 2016Date of Patent: January 14, 2020Assignees: Catherex, Inc., Georgetown University, The General Hospital CorporationInventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
-
Patent number: 10532096Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.Type: GrantFiled: April 23, 2018Date of Patent: January 14, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Ella Ioffe, Israel Lowy, Gavin Thurston, Elena Burova
-
Patent number: 10532097Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.Type: GrantFiled: July 10, 2015Date of Patent: January 14, 2020Assignee: Academia SinicaInventors: Patrick C. H. Hsieh, Pei-Jung Wu, Steve Roffler, Bill Cheng
-
Patent number: 10532098Abstract: The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n=2-12.Type: GrantFiled: January 30, 2013Date of Patent: January 14, 2020Assignee: Arecor LimitedInventors: Jan Jezek, Guy Casy, Barry Kingston Derham, Nikki Royle
-
Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
Patent number: 10532099Abstract: Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.Type: GrantFiled: October 18, 2017Date of Patent: January 14, 2020Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock -
Patent number: 10532100Abstract: The invention relates to the use of iron for preparing a medicament for the preventive and/or curative treatment of attention deficit hyperactivity disorder (ADHD) or at least one of the symptoms thereof, for a patient requiring such treatment.Type: GrantFiled: June 1, 2004Date of Patent: January 14, 2020Assignee: NLS PHARMA AGInventor: Eric Konofal
-
Patent number: 10532101Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.Type: GrantFiled: September 9, 2019Date of Patent: January 14, 2020Assignee: AXSOME THERAPEUTICS, INC.Inventor: Herriot Tabuteau
-
Patent number: 10532102Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.Type: GrantFiled: August 18, 2017Date of Patent: January 14, 2020Assignee: Foresee Pharmaceuticals Co., Ltd.Inventors: Yuhua Li, ChiaTing Huang, John Mao
-
Patent number: 10532103Abstract: The present application provides bifunctional compounds of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 9 (CDK9), the present application also relates to methods for the targeted degradation of CDK9 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK9 which can be utilized in the treatment of disorders modulated by CDK9.Type: GrantFiled: April 21, 2017Date of Patent: January 14, 2020Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Tinghu Zhang, Calla M. Olson, Yanke Liang, Nicholas Kwiatkowski
-
Patent number: 10532104Abstract: Described herein are compositions and methods for treating or imaging Alzheimer's disease (AD). The compositions comprise a biotin moiety and a siRNA moiety, without the need for a targeting agent such as an antibody, avidin, or streptavidin. In certain embodiments, the compositions further comprise a diagnostic agent.Type: GrantFiled: May 22, 2017Date of Patent: January 14, 2020Assignee: The General Hospital CorporationInventor: David R. Elmaleh
-
Patent number: 10532105Abstract: Novel amphiphilic peptide, peptide amphiphile lipid micelles, processes for making peptide amphiphile lipid micelles comprising an amphiphilic peptide and phospholipid and optionally comprising a cargo molecule, and methods of use.Type: GrantFiled: July 8, 2016Date of Patent: January 14, 2020Assignee: Peptinovo Biopharma, LLC.Inventors: Reynold Homan, William L. Elliott
-
Patent number: 10532106Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.Type: GrantFiled: October 29, 2015Date of Patent: January 14, 2020Assignee: BICYCLERD LIMITEDInventors: Daniel Paul Teufel, Catherine Lucy Stace, Silvia Pavan, Edward Walker, Leonardo Baldassare
-
Patent number: 10532107Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.Type: GrantFiled: October 20, 2015Date of Patent: January 14, 2020Assignee: SAIBA GMBHInventors: Martin Bachmann, Andris Zeltins, Paul Pumpens
-
Patent number: 10532108Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.Type: GrantFiled: February 8, 2019Date of Patent: January 14, 2020Assignee: GENENTECH, INC.Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Vishal Verma, Donglu Zhang
-
Patent number: 10532109Abstract: Provided herein are therapeutic agents having specificity for having inhibitory activity against cancer cells that overexpress human epidermal growth factor receptor (HER) genes, including therapeutic agents comprising one or more HER-targeting peptides, pharmaceutical compositions comprising such therapeutic agents, and methods of using such compositions to treat or prevent a cancer or other disease condition associated with HER overexpression.Type: GrantFiled: May 8, 2017Date of Patent: January 14, 2020Assignee: Arizona Board of Regents on behalf of Arizona State UniversityInventors: Shengxi Chen, Yanmin Zhang, Sidney Hecht
-
Patent number: 10532110Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.Type: GrantFiled: November 20, 2015Date of Patent: January 14, 2020Assignee: The University of North Carolina at Chapel HillInventors: Steven Gray, Thomas McCown
-
Patent number: 10532111Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i.e., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.Type: GrantFiled: August 18, 2017Date of Patent: January 14, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark A. Kay, Nicole K. Paulk
-
Patent number: 10532112Abstract: An object of the present invention is to provide a method for producing a non-human primate model of AMD, a method for evaluating the efficacy of a test substance in the prevention or treatment of AMD using the AMD animal model produced according to this method, and a method for screening substances effective in the prevention or treatment of AMD using the aforementioned AMD animal model. The method for preparing the AMD animal model consists of administering sodium iodate into a vitreous body of a non-human primate, and the method for evaluating the efficacy of a test substance in the prevention or treatment of AMD consists of preparing a non-human primate model of AMD according to the aforementioned method for preparing an AMD animal model, and evaluating the efficacy of the test substance in the prevention or treatment of AMD using the resulting AMD animal model.Type: GrantFiled: December 22, 2017Date of Patent: January 14, 2020Assignees: Hamamatsu Pharma Research, Inc.Inventor: Hiroyuki Takamatsu
-
Patent number: 10532113Abstract: Polymeric systems useful for theranostic applications are disclosed. The polymeric systems comprise a fluorescent or fluorogenic moiety and a therapeutically active agent, each attached to the same or different polymeric moiety. The polymeric systems are designed such that a fluorescent signal is generated in response to a chemical event, preferably upon contacting an analyte (e.g., an enzyme) that is over-expressed in a diseased tissue or organ. Probes useful for inclusion in such polymeric systems, processes of preparing such probes and the polymeric systems, and uses thereof in diagnostic and/or theranostic applications are also disclosed.Type: GrantFiled: March 13, 2015Date of Patent: January 14, 2020Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Ronit Satchi-Fainaro, Doron Shabat, Rachel Blau, Yana Epshtein, Hemda Baabur-Cohen, Shiran Ferber, Orit Redy-Keisar, Einat Kisin-Finfer
-
Patent number: 10532114Abstract: A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprises a compound having the general chemical formula: Ca10?yGdy(PO4)6?x(SiO4)x(OH)2?c+y where 0<x<1.3 and 0<y<1.3.Type: GrantFiled: January 27, 2017Date of Patent: January 14, 2020Assignees: ApaTech Limited, University Court of the University of AberdeenInventors: Iain Ronald Gibson, Janet Mabel Scott Skakle, Nigel Smith, Thomas Buckland
-
Patent number: 10532115Abstract: The present invention relates to systems and methods to facilitate replacement between runs of a kit or cassette from an automated radiosynthesis device located in a hot cell. The method and apparatus of the invention enable automated disconnection of the outlet line by sealing the tubing hermetically by means of heat and by cutting the tubing where it is sealed in such a way that there is no risk of environmental contamination with radioactive material. The invention enables disconnection of the outlet line without manual intervention before opening the shielded enclosure.Type: GrantFiled: March 30, 2015Date of Patent: January 14, 2020Assignee: GE HEALTHCARE LIMITEDInventors: Christoph Mosdzianowski, Philippe Dumont, Sali Kuci
-
Patent number: 10532116Abstract: A processing unit and method for separating hydrocarbons from feedstock material. The processing unit includes at least one rotating conveyor in communication with a material inlet and a material outlet; a vacuum pump providing a vacuum atmosphere within the rotating conveyor; at least one material transfer device positioned at the material inlet and at least one material transfer device positioned at the material outlet, each material transfer device configured to allow transfer of feedstock material into or out of the rotating conveyor whilst maintaining the vacuum atmosphere within the rotating conveyor; and an electrostatic generator connected to the rotating conveyor providing a static charge to the vacuum atmosphere within the rotating conveyor.Type: GrantFiled: April 6, 2017Date of Patent: January 14, 2020Assignee: FULCRUM ENERGY CORPORATIONInventor: Phillip Cauley
-
Patent number: 10532117Abstract: Medical containers are provided, wherein the containers may be used to transport medical devices. The medical container can include a front panel, a rear panel, and a lower panel cooperating to form a cavity. The lower panel may include an absorbent material. The medical container may also include one or more absorbent band members disposed around at least a portion of the circumference of the cavity. An insert portion including a front panel, a rear panel, and a lower panel may be coupled to or disposed within the medical container. The insert portion may be formed from an absorbent material. Methods of using the medical containers are also provided.Type: GrantFiled: October 6, 2016Date of Patent: January 14, 2020Assignee: Merit Medical Systems, Inc.Inventors: Aaron Hopkinson, Doug Hales, Daniel Hadley, Dylan Neyme, John William Hall, Jeremy Snow, Tyler David Rees, Abbe M. Smith